ANPCY News and Press, Angle Plc Surrey ADR From 04/13/23

2023-04-13 05:00:23 ET Liquid biopsy company, ANGLE ( OTCQX:ANPCY ) has signed a contract with a new customer, Crescendo Biologics. Crescendo is a UK-based, clinical stage immuno-oncology company with an extensive proprietary pipeline of novel, targeted T cell enhanc...

Crescendo to use ANGLE's recently launched Portrait Flex Assay in prostate cancer study GUILDFORD, SURREY / ACCESSWIRE / April 13, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed a contract with a new customer, Cresc...

Joseph Eid M.D., is a US certified medical oncologist with extensive experience of the use of biomarkers in clinical trials and as companion diagnostics Previous roles include senior positions in oncology at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche GUILDFORD, SURREY / A...

Experienced life science executive, Juliet Thompson, joins ANGLE Board with immediate effect GUILDFORD, SURREY / ACCESSWIRE / January 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Juliet Thompson has been ap...

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to provide a review of business progress, an unaudited trading update for 2022 and prospects for 2023. 2022: a breakthrough year GUILDFORD, SURREY / ACCESSWIRE / January 5, 2023 / 2022 has been a breakthr...

TWO PARSORTIX POSTERS PRESENTED AT LEADING BREAST CANCER CONFERENCE Studies demonstrate the utility of the Parsortix PC1 Clinical System to isolate and harvest CTCs from metastatic breast cancer patients for further downstream analysis Harvested CTCs underwent cytological, immunofluores...

CTCS ISOLATED BY THE PARSORTIX SYSTEM FROM METASTATIC BREAST CANCER PATIENTS CAN BE ANALYSED BY MULTIPLE DOWNSTREAM TECHNIQUES Publication of results from ANGLE's multi-centre clinical study in collaboration with leading US cancer centres Data from the study contributed to the succ...

PARSORTIX POSTER PRESENTED AT INTERNATIONAL SOCIETY OF LIQUID BIOPSY MEETING Study demonstrates ability to analyse both CTCs and ctDNA from the same sample Value of multimodal analyte analysis in liquid biopsy gaining recognition and momentum GUILDFORD, SURREY / ACCESSWIRE / Oc...

Cost savings of c. £2.6 million in 2023 rising to c. £4.0 million per annum thereafter No significant impact on ongoing operations expected GUILDFORD, SURREY / ACCESSWIRE / October 18, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announc...

GUILDFORD, UK / ACCESSWIRE / October 17, 2022 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Unite...